IFF Launches Re-Imagine…™ Programs to Tap Unmet Consumer Opportunities, Speed Innovation
International Flavors & Fragrances Inc. (NYSE:IFF) (Euronext Paris:IFF), a leading innovator of sensory experiences that move the world, launched their Re-Imagine programs to accelerate innovation and increase agility to capture unmet opportunities in the changing food and beverage market. Based on a combination of future trends analysis, consumer insights, and a modernized cross-category development process, the programs guide the Company’s research and development efforts to ensure an innovation pipeline that addresses evolving consumer needs and desires.
“The Re-Imagine programs area tangible expression of our commitment to advance taste for our customers – and consumers,” said IFF Chairman and CEO Andreas Fibig. “It is another way in which we show how we are dedicated to being our customers’ partner of choice as we progress on our business strategy, imbue sustainable thinking throughout the creation process, and continue to strengthen our industry-leading innovation platforms.”
“The programs were developed to outpace rapidly changing dynamics and anticipate market shifts that were unimaginable just a few years ago,” said Matthias Haeni, IFF Group President, Flavors. “Our customers aren’t looking for just a better strawberry. They are looking for answers to questions beyond traditional flavor, requiring a hands-on, artisanal approach to making their iconic tastes come to life. We are essentially rethinking the traditional end-use approach of our industry to design technologies with the versatility to deliver differentiation across multiple categories and applications. This demonstrates IFF’s commitment to making bigger and bolder bets on where the market is heading.”
The programs focus on six key areas, including culinary, citrus, delivery systems, naturals, modulation and protein and were selected based on market potential, customer input, expert industry collaboration and versatility across end-use categories. They consider a rapidly changing world – from the expectations of sophisticated consumers too busy to cook for themselves; to the realities of a warming climate and its impact on key crops and ingredients; to an increased awareness of our role in the health of the planet.
Mr. Haeni continued, “Our expansive innovation platform required an innovative approach to taste creation. To address this, our bespoke IFF Taste Design™ is a combination of artisanal, handcrafted techniques and proprietary technologies that drive consumer preference and market differentiation. We believe that both our Re-Imagine programs and our IFF Taste Design approach will provide our customers with winning tastes and further establish us as their essential partner.” More information on the Re-Imagine programs can be found on the Company’s website .
# # #
International Flavors & Fragrances Inc. (NYSE:IFF) (Euronext Paris: IFF) is a leading innovator of sensorial experiences that move the world. At the heart of our company, we are fueled by a sense of discovery, constantly asking “what if?”. That passion for exploration drives us to co-create unique products that consumers taste, smell, or feel in fine fragrances and beauty, detergents and household goods, as well as beloved foods and beverages. Our 7,400 team members globally take advantage of leading consumer insights, research and development, creative expertise, and customer intimacy to develop differentiated offerings for consumer products. Learn more at www.iff.com , Twitter , Facebook , Instagram , and LinkedIn .
International Flavors & Fragrances Inc.
Michael DeVeau, 212-708-7164
VP, Corporate Strategy, Investor Relations & Communications
Information om Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco
Følg pressemeddelelser fra Business Wire
Skriv dig op her og modtag pressemeddelelser på mail. Indtast din mail, klik på abonner og følg instruktionerne i den udsendte mail.
Flere pressemeddelelser fra Business Wire
DE-INCYTE21.10.2018 12:47 | pressemeddelelse
Incyte Announces Positive Interim Data from Phase 2 Trial of Pemigatinib, Its Selective FGFR Inhibitor, in Patients with Cholangiocarcinoma
SERVIER21.10.2018 11:12 | pressemeddelelse
Servier and Taiho Oncology Announce Phase III LONSURF® Study Has Met Primary and Secondary Endpoints Demonstrating Prolonged Overall Survival and Progression-Free Survival in Patients with Refractory Metastatic Gastric Cancer
IL-GILEAD-SCIENCES21.10.2018 00:32 | pressemeddelelse
Phase 3 Data on Filgotinib in Biologic-Experienced Rheumatoid Arthritis to Be Presented at 2018 ACR/ARHP Annual Meeting
CA-TRUE-RELIGION19.10.2018 19:39 | pressemeddelelse
Manchester United and True Religion Launch Denim Range
ARCH-INSURANCE19.10.2018 15:12 | pressemeddelelse
Arch Insurance Announces Strategic Leadership Changes
MA-TAKEDA-PHARMACEUTICAL19.10.2018 14:02 | pressemeddelelse
Takeda to Present Results from Phase 3 ALTA-1L Trial Highlighting Intracranial Efficacy of ALUNBRIG® (brigatinib) Versus Crizotinib in First-Line Advanced ALK+ Non-Small Cell Lung Cancer
I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter, og finde vores kontaktoplysninger.Besøg vores nyhedsrum